At a glance
| Field | Details |
|---|---|
| Brand names | Not yet approved |
| Targets | GLP-1R + GCGR |
| Developer | Boehringer Ingelheim / Zealand Pharma |
| Modality | SC injection, once-weekly |
| Approval status | Phase 3 |
| Key efficacy | ~19% weight loss at 46 weeks (Phase 2, obesity) |
| Indications | Obesity, MASH |
User Sentiment
Survodutide's community is primarily MASH patients and their caregivers — a group that's been watching GLP-1/glucagon data closely because MASH had almost no pharmacological treatment options until recently. The obesity trial participants report strong appetite suppression, with the glucagon component noted as producing a distinct "metabolic shift" feeling beyond standard GLP-1 effects.
Example(What the community says)
MASH patient forums light up around survodutide Phase 2 data in ways that weight loss posts don't — because for that population, a drug showing 67% MASH resolution represents the first real pharmacological option for a condition that previously had none. The emotional stakes in those communities are different from pure obesity treatment discussions.
How it works
GLP-1/glucagon dual agonist — mechanistically distinct from the GLP-1/GIP branch. GLP-1R drives appetite suppression and insulin secretion. GCGR activation adds resting energy expenditure and hepatic fat oxidation — effects that GLP-1 alone and GLP-1/GIP drugs don't provide. The glucagon component directly mobilizes fat from the liver, which is the primary reason survodutide is the leading drug in the MASH indication alongside its obesity development.
Intuition(Why glucagon is good for the liver)
Glucagon is best known for raising blood glucose by stimulating hepatic glucose production — the opposite of what you want in a diabetes or obesity drug. But glucagon also directly activates fat oxidation in the liver, driving hepatic fat breakdown independent of weight loss. MASH (metabolic dysfunction-associated steatohepatitis) is driven by hepatic fat accumulation and the inflammation that follows. GLP-1 drugs improve MASH through weight loss. GLP-1/glucagon drugs add a direct liver mechanism on top of that — which is why survodutide's 67% MASH resolution rate in Phase 2 is higher than any pure weight-loss drug would predict.
Trial data
Phase 2 obesity (46 weeks): ~19% weight loss — competitive with tirzepatide's Phase 2 numbers, though different populations and doses limit direct comparison.
Phase 2 MASH: ~67% of patients achieved MASH resolution without worsening of fibrosis — a striking number in a disease where lifestyle modification had been the primary treatment until recently. The glucagon agonism mechanism driving hepatic fat oxidation is believed to underlie this effect.
What to Expect
Weeks 1–4 — Slower titration than tirzepatide due to the glucagon component requiring careful glucose management. GI side effects similar to class, nausea most common.
Month 2–4 — Appetite reduction and energy expenditure increase both reported — the latter is distinct from GLP-1-only drugs and reflects the GCGR component at work.
Month 6+ — Phase 2 weight loss of ~19% at 46 weeks puts the expected trajectory in the tirzepatide range. MASH patients: liver fat reduction and histology improvement typically visible in blood markers and imaging within 6 months.
Dosing and administration
Once-weekly subcutaneous injection. Slower titration schedule than GLP-1-only drugs due to glucagon's glucose-raising effect requiring careful balance. Phase 3 titration schedule [verify against final protocol].
Development status
| Milestone | Status |
|---|---|
| Phase 2 obesity | Complete — ~19% weight loss |
| Phase 2 MASH | Complete — ~67% resolution |
| Phase 3 obesity | Enrolling |
| Phase 3 MASH | Enrolling |
| FDA filing | ~2027 estimated |
Safety profile
GI profile similar to GLP-1 class. Glucagon component raises theoretical hyperglycemia concern in non-diabetic patients — manageable within dose ranges tested in Phase 2 through careful titration. Heart rate elevation similar to class. Phase 3 will be the definitive tolerability read at longer duration.
Who It's For
- BMI ≥ 30 or ≥ 27 with a weight-related condition
- MASH patients specifically — if you have metabolic liver disease, survodutide's Phase 2 data is the most compelling pharmacological signal for this indication
- People who haven't responded fully to GLP-1-only approaches and want the added energy expenditure from glucagon agonism
Currently Phase 3 — not yet available for prescription. Talk to a hepatologist or endocrinologist about trial eligibility if you have MASH.
Summary(The survodutide picture)
~19% Phase 2 weight loss is competitive with the GLP-1/GIP branch. The MASH resolution data (~67% without fibrosis worsening) is the clinically distinctive number — potentially the highest ever seen for a pharmacological agent in liver disease. If Phase 3 confirms both, survodutide has two registration paths: obesity and MASH as distinct indications.